ABS (ABS) Fair Value & Analysis
Healthcare · NO · Market cap 89.0M NOK
Fair value as of: Jun 24, 2026
From 2 valuation models · updated 5 days ago
Price vs Fair Value (12 months)
12‑month range kr 2.86 – kr 4.01 · fair‑value band kr 21.72 – kr 36.20 · the kr 3.15 price screens below the kr 28.96 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
ABS (ABS) currently trades at kr 3.15, while our model-based Fair Value estimate is kr 28.96 — implying the stock looks roughly 819.4% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, ABS generated revenue of 42.6M NOK at a net margin of -96.3%. Revenue declined 12.0% year over year. It earns a return on equity of -21.4%. Net debt stands at 63.1M NOK. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Arctic Bioscience AS, a clinical-stage biotechnology company, engages in developing and commercializing pharmaceutical and nutraceutical ingredients based on bioactive marine compounds in Norway, the United States, Europe, and Asia Pacific. The company is developing HRO350, a novel oral drug which is in phase IIb for the treatment of mild-to-moderate psoriasis; and the HeROPA study, an international phase IIb clinical trial. It also sells nutraceuticals as an intermediary and finished goods products under the ROMEGA brand name. Arctic Bioscience AS was incorporated in 2011 and is headquartered in Ørsta, Norway.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
ABS reported revenue of kr 40.1M in FY2025 versus kr 21.5M in FY2021, a compound +16.8%/yr. Reported net income was −kr 41.0M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$562.61 | R$385.38 | -32% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €274.90 | €211.40 | -23% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $286.41 | $106.81 | -63% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is ABS (ABS) undervalued?
What is the fair value of ABS?
What is the quality score of ABS?
What is the revenue of ABS (ABS)?
What is the net profit margin of ABS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.